CN106215124A - 平肝胶囊及其制备方法和应用 - Google Patents
平肝胶囊及其制备方法和应用 Download PDFInfo
- Publication number
- CN106215124A CN106215124A CN201610795187.8A CN201610795187A CN106215124A CN 106215124 A CN106215124 A CN 106215124A CN 201610795187 A CN201610795187 A CN 201610795187A CN 106215124 A CN106215124 A CN 106215124A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- fructus
- parched
- brown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 55
- 239000010341 ping gan Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 49
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 20
- 241000489492 Arisaema Species 0.000 claims abstract description 18
- 210000000941 bile Anatomy 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 239000010271 massa medicata fermentata Substances 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims description 50
- 239000013543 active substance Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 208000002672 hepatitis B Diseases 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 2
- 235000019640 taste Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 18
- 208000011580 syndromic disease Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 231100000614 poison Toxicity 0.000 abstract description 6
- 239000003440 toxic substance Substances 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000003908 liver function Effects 0.000 description 7
- 239000003292 glue Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- -1 polysorbate60-80 Chemical compound 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 206010041519 Spider naevus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,具体涉及一种平肝胶囊及其制备方法和应用。所述平肝胶囊由如下重量份配比的原料药制成:茵陈10‑20份、龙胆草10‑20份、黄芩10‑20份、夏枯草10‑20份、马鞭草10‑20份、胆南星10‑20份、绿豆10‑20份、柴胡10‑20份、紫草5‑15份、郁金10‑20份、虎杖10‑20份、羚羊角5‑15份、茯苓10‑20份、枳壳15‑25份、甘草5‑15份、五味子10‑20份、栀子10‑20份、半枝莲10‑20份、焦麦芽10‑20份、焦山楂10‑20份、焦神曲10‑20份。诸药合用,共奏平肝熄风、清肝解毒、活血化瘀、理气止痛的功效。
Description
技术领域
本发明属于医药技术领域,具体涉及一种平肝胶囊及其制备方法和应用。
背景技术
慢性乙型病毒性肝炎是由乙型肝炎病毒感染人体及机体免疫功能低下所引起的以肝脏损伤为主的全身性疾病,是严重危害人类生命健康的传染病。本病流行范围之广、传播途径之复杂、发病率之高、危害性之大,居各种传染病之首。慢性乙型肝炎几乎在全球范围内分布,全世界慢性乙型肝炎感染者超过3.5亿人。我国的慢性无症状乙型肝炎病毒携带者可能超过1.2亿,现患有乙型肝炎者为2800万人,年感染率约为2700/10万,年发病率为230/10万。目前临床治疗尚未取得满意疗效,是亟待攻克的三大疑难疾病之一。
发明内容
为了解决上述的技术问题,本发明提供了一种平肝胶囊及其制备方法。
一种平肝胶囊,由如下重量份配比的原料药制成:
茵陈10-20份、龙胆草10-20份、黄芩10-20份、夏枯草10-20份、马鞭草10-20份、胆南星10-20份、绿豆10-20份、柴胡10-20份、紫草5-15份、郁金10-20份、虎杖10-20份、羚羊角5-15份、茯苓10-20份、枳壳15-25份、甘草5-15份、五味子10-20份、栀子10-20份、半枝莲10-20份、焦麦芽10-20份、焦山楂10-20份、焦神曲10-20份。
优选的,上述的平肝胶囊,由如下重量份配比的原料药制成:
茵陈13-17份、龙胆草13-17份、黄芩13-17份、夏枯草13-17份、马鞭草13-17份、胆南星13-17份、绿豆13-17份、柴胡13-17份、紫草8-12份、郁金13-17份、虎杖13-17份、羚羊角8-12份、茯苓13-17份、枳壳18-22份、甘草8-12份、五味子13-17份、栀子13-17份、半枝莲13-17份、焦麦芽13-17份、焦山楂13-17份、焦神曲13-17份。
更优选的,上述的平肝胶囊,由如下重量份配比的原料药制成:
茵陈15份、龙胆草15份、黄芩15份、夏枯草15份、马鞭草15份、胆南星15份、绿豆15份、柴胡15份、紫草10份、郁金15份、虎杖15份、羚羊角10份、茯苓15份、枳壳20份、甘草10份、五味子15份、栀子15份、半枝莲15份、焦麦芽15份、焦山楂15份、焦神曲15份。
本发明的以上组成中,各味中药的重量是以生药计算的,如果以克为单位,如制成制剂,则因制剂的大小不同可制成100-1000剂。所述100-1000剂是指单位剂量的制剂形式,如片剂100-1000片,胶囊剂100-1000粒,颗粒剂100-1000g,口服液100-1000ml,膏剂100-1000g,丸剂100-1000丸等。
以上组成是按重量作为配比的,在生产时可按照相应比例增大或减少,如大规模生产可以以kg为单位,或以t(吨)为单位;小规模制剂也可以以g为单位。重量可以增大或者减小,但各组成之间的生药材重量配比的比例不变。
以上重量配比的比例是经过科学筛选得到的,对于特殊病人,如重症或轻症,肥胖或瘦小的病人,可以相应调整组成的量的配比,增加或减少不超过100%,药效基本不变。
本发明的平肝胶囊,可单独或根据需要可以加入一些药物可接受的辅料,可以采用制剂学常规技术制备该药物制剂。在制成药物制剂时可以制成任何可药用的口服剂型,这些剂型选自:颗粒剂、片剂、胶囊剂、口服液、口含剂、丸剂、散剂,优选为胶囊剂。
上述的平肝胶囊的制备方法,包含如下步骤:
(1)羚羊角研成细粉,过100目筛,备用;
(2)龙胆草、黄芩、胆南星、郁金、茯苓、五味子六味粉碎成细粉,得药粉A;
(3)其余茵陈等十四味药加水煎煮三次,第一次加药物重量8倍量水,第二、三次加药物重量6倍量水,每次煎煮2小时,过滤,合并煎液,浓缩至稠膏,干燥粉碎,得药粉B;
(4)将药粉A、药粉B与步骤(1)制得的羚羊角细粉混合使均匀,即得本发明平肝胶囊的活性物质;
(5)该活性物质单独或与药物可接受的辅料混合,按照制剂学常规方法制得。
所述的药物可接受的辅料选自:淀粉、硬脂酸镁、甘露醇、山梨醇、山梨酸或钾盐、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素A、维生素C、维生素E、维生素D、氮酮、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、右旋糖苷、甘氨酸、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、丙二醇、乙醇、吐温60-80、司班-80、蜂蜡、羊毛脂、液体石蜡、十六醇、没食子酸酯类、三乙醇胺、碱性氨基酸、尿素、尿囊素、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙等。
上述的平肝胶囊制备治疗慢性乙型肝炎药物中的应用。
本发明的平肝胶囊的用法用量:口服,每次5-8粒,每日2-3次,或遵医嘱。
本方主要用于治疗肝阳上亢、肝风内动、气滞血瘀、肝区疼痛、转氨酶增高、恶心、乏力、纳差等。本发明的平肝胶囊的处方中,采用羚羊角、胆草清肝解毒,降低转氨酶,黄芩、马鞭草、半枝莲、夏枯草、紫草、茵陈、郁金、虎杖、栀子、胆星、绿豆加强解毒清肝之功效,柴胡疏肝理气、平肝息风使肝气调达,茯苓、枳壳和中健胃行气,五味子敛肝阴,甘草调和诸药和中健胃,本方是降肝功而不伤正之良方。诸药合用,共奏平肝熄风、清肝解毒、活血化瘀、理气止痛的功效。
平肝胶囊临床用于热毒内蕴、气滞血瘀所引起的各类型肝炎、肝硬化、肝胆湿热。本方有较强的平肝熄风、清肝解毒、活血化瘀、理气止痛作用,对各种因素引起的转氨酶,转肽酶等肝功能指标增高有降低和恢复作用,并能促进HBeAg转阴,临床总有效率为98.57%,愈显率达87.14%,且安全性高。
具体实施方式
下面结合具体实施例对本发明作更进一步的说明,以便本领域的技术人员更了解本发明,但并不因此限制本发明。
实施例1
一种平肝胶囊,由如下重量配比的原料药制成:
茵陈15g、龙胆草15g、黄芩15g、夏枯草15g、马鞭草15g、胆南星15g、绿豆15g、柴胡15g、紫草10g、郁金15g、虎杖15g、羚羊角10g、茯苓15g、枳壳20g、甘草10g、五味子15g、栀子15g、半枝莲15g、焦麦芽15g、焦山楂15g、焦神曲15g。
该平肝胶囊的制备方法:
(1)羚羊角研成细粉,过100目筛,备用;
(2)龙胆草、黄芩、胆南星、郁金、茯苓、五味子六味粉碎成细粉,得药粉A;
(3)其余茵陈等十四味药加水煎煮三次,第一次加药物重量8倍量水,第二、三次加药物重量6倍量水,每次煎煮2小时,过滤,合并煎液,浓缩至稠膏,干燥粉碎,得药粉B;
(4)将药粉A、药粉B与步骤(1)制得的羚羊角细粉混合使均匀,即得本发明平肝胶囊的活性物质;
(5)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊600粒。
实施例2
一种平肝胶囊,由如下重量配比的原料药制成:
茵陈13g、龙胆草17g、黄芩13g、夏枯草17g、马鞭草13g、胆南星17g、绿豆13g、柴胡17g、紫草8g、郁金17g、虎杖13g、羚羊角12g、茯苓13g、枳壳22g、甘草8g、五味子17g、栀子13g、半枝莲17g、焦麦芽13g、焦山楂17g、焦神曲13g。
该平肝胶囊的制备方法:
(1)羚羊角研成细粉,过100目筛,备用;
(2)龙胆草、黄芩、胆南星、郁金、茯苓、五味子六味粉碎成细粉,得药粉A;
(3)其余茵陈等十四味药加水煎煮三次,第一次加药物重量8倍量水,第二、三次加药物重量6倍量水,每次煎煮2小时,过滤,合并煎液,浓缩至稠膏,干燥粉碎,得药粉B;
(4)将药粉A、药粉B与步骤(1)制得的羚羊角细粉混合使均匀,即得本发明平肝胶囊的活性物质;
(5)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊600粒。
实施例3
一种平肝胶囊,由如下重量配比的原料药制成:
茵陈17g、龙胆草13g、黄芩17g、夏枯草13g、马鞭草17g、胆南星13g、绿豆17g、柴胡13g、紫草12g、郁金13g、虎杖17g、羚羊角8g、茯苓17g、枳壳18g、甘草12g、五味子13g、栀子17g、半枝莲13g、焦麦芽17g、焦山楂13g、焦神曲17g。
该平肝胶囊的制备方法:
(1)羚羊角研成细粉,过100目筛,备用;
(2)龙胆草、黄芩、胆南星、郁金、茯苓、五味子六味粉碎成细粉,得药粉A;
(3)其余茵陈等十四味药加水煎煮三次,第一次加药物重量8倍量水,第二、三次加药物重量6倍量水,每次煎煮2小时,过滤,合并煎液,浓缩至稠膏,干燥粉碎,得药粉B;
(4)将药粉A、药粉B与步骤(1)制得的羚羊角细粉混合使均匀,即得本发明平肝胶囊的活性物质;
(5)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊600粒。
实施例4
一种平肝胶囊,由如下重量配比的原料药制成:
茵陈10g、龙胆草20g、黄芩10g、夏枯草20g、马鞭草10g、胆南星20g、绿豆10g、柴胡20g、紫草5g、郁金20g、虎杖10g、羚羊角15g、茯苓10g、枳壳25g、甘草5g、五味子20g、栀子10g、半枝莲20g、焦麦芽10g、焦山楂20g、焦神曲10g。
该平肝胶囊的制备方法:
(1)羚羊角研成细粉,过100目筛,备用:
(2)龙胆草、黄芩、胆南星、郁金、茯苓、五味子六味粉碎成细粉,得药粉A;
(3)其余茵陈等十四味药加水煎煮三次,第一次加药物重量8倍量水,第二、三次加药物重量6倍量水,每次煎煮2小时,过滤,合并煎液,浓缩至稠膏,干燥粉碎,得药粉B;
(4)将药粉A、药粉B与步骤(1)制得的羚羊角细粉混合使均匀,即得本发明平肝胶囊的活性物质;
(5)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊600粒。
实施例5
一种平肝胶囊,由如下重量配比的原料药制成:
茵陈20g、龙胆草10g、黄芩20g、夏枯草10g、马鞭草20g、胆南星10g、绿豆20g、柴胡10g、紫草15g、郁金10g、虎杖20g、羚羊角5g、茯苓20g、枳壳15g、甘草15g、五味子10g、栀子20g、半枝莲10g、焦麦芽20g、焦山楂10g、焦神曲20g。
该平肝胶囊的制备方法:
(1)羚羊角研成细粉,过100目筛,备用;
(2)龙胆草、黄芩、胆南星、郁金、茯苓、五味子六味粉碎成细粉,得药粉A;
(3)其余茵陈等十四味药加水煎煮三次,第一次加药物重量8倍量水,第二、三次加药物重量6倍量水,每次煎煮2小时,过滤,合并煎液,浓缩至稠膏,干燥粉碎,得药粉B;
(4)将药粉A、药粉B与步骤(1)制得的羚羊角细粉混合使均匀,即得本发明平肝胶囊的活性物质;
(5)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊600粒。
对实施例1制备的平肝胶囊进行了临床试验,详情如下:
1.资料与方法
1.1 一般资料
选取确诊为慢性乙型病毒性肝炎患者140例,随机分为对照组和观察组。对照组70例患者,男性39例,女性31例,年龄18~71岁,平均年龄(49.83±13.53)岁,病程为1年至7年,平均病程为(3.37±1.24)年。观察组70例患者,男性42例,女性28例,年龄18~73岁,平均年龄(48.35±11.27)岁,病程为11个月至9年,平均病程为(3.92±1.39)年。两组患者年龄、性别、病程等基本资料比较无统计学意义(P>0.05),具有可比性。
1.1.2 诊断标准:
西医诊断标准:参照中华医学会传染病与寄生虫病学分会、肝病学会联合修定的《病毒性肝炎防治方案》中有关慢性乙型病毒性肝炎的诊断标准而制定。
中医诊断标准:参照《中药新药临床研究指导原则》中相关诊断标准,属热毒内蕴、气滞血瘀证,症见胁肋疼痛、口干苦、腹胀满、便秘、乏力、恶心、。
1.1.3 纳入病例标准
(1)年龄在18-75岁;
(2)临床诊断符合中西医诊断标准;
(3)受试知情,并签署知情同意书。
1.1.4 排除病例标准
(1)年龄在18岁以下(不包括18岁),或75岁以上(不包括75岁);
(2)妊娠或哺乳期妇女;
(4)凡病情危重,无法判断疗效或安全性者;
(5)同时服用激素、保肝降酶药物;
(6)过敏体质及对受试药物处方中药物过敏者。
1.2 方法
1.2.1 治疗方法
观察组给予本发明的平肝胶囊,口服,一次5-8粒,每日2-3次,或遵医嘱。
对照组予以口服乙肝清热解毒片(主要由虎杖、白花蛇舌草、北豆根、茵陈等组成,山东海森药业有限公司生产)。该药能清热解毒化湿,功用主治与试验用药相近,是目前国内疗效较为肯定的法定同类药物,符合公认有效、安全、可比原则。
4周为一疗程。
1.2.2 疗效观察指标
1)症状、体征:如观察胁痛、食欲、乏力、腹胀、黄疽、肝脾肿大、肝掌、蜘蛛痣、蛆血、舌苔、脉象等,采用积分法记录。按无、轻、中、重分别记为0、1、2、3分。
2)病原学指标:HBeAg转阴率。
3)肝功能指标:观察谷丙转氨酶(ALT)、谷草转氨酶(AST)、谷胺酰转肽酶(GGT)。
4)安全性指标:三大常规、肾功及心电图。
1.2.3 疗效判定标准
参照《中药新药临床研究指导原则》,分为治愈、显效、有效和无效。
痊愈:中医临床症状、体征明显改善,证候积分减少≥90%;
显效:中医临床症状、体征明显改善,证候积分减少≥70%;
有效:中医临床症状、体征均有好转,证候积分减少≥30%;
无效:中医临床症状、体征均无明显改善,甚或加重,证候积分减少不足30%。
1.2.4 统计学处理
采用SPSS16.0软件对数据进行统计学处理,计数资料采用t检验,以P<0.05为有显著差异性,提示有统计学意义。
2.结果
2.1 两组治疗前后肝功能指标变化
治疗前两组的肝功能比较差异无统计学意义(P>0.05),具有可比性;治疗后两组患者肝功能均较术前明显改善,差异具有统计学意义(P<0.05),但观察组的改善程度均明显优于对照组,差异具有统计学意义(P<0.05);见表1。
表1 治疗前后肝功能指标变化
注:*表示与治疗前比较P<0.05;#表示与对照组治疗后比较P<0.05
2.2 两组临床疗效比较
治疗后两组的证候积分均较治疗前明显降低,差异具有统计学意义(P<0.05);观察组降低程度明显优于对照组,差异具有统计学意义(P<0.05);观察组临床显效率和总有效率均明显高于对照组,差异具有统计学意义(P<0.05),见表2、3。
表2 两组治疗前后证候积分比较
注:*表示与治疗前比较P<0.05;#表示与对照组治疗后比较P<0.05。
表3 两组临床疗效比较(例)
组别 | n | 治愈 | 显效 | 有效 | 无效 | 愈显率(%) | 总有效率(%) |
观察组 | 70 | 33 | 28 | 8 | 1 | 87.14* | 98.57** |
对照组 | 70 | 13 | 30 | 12 | 15 | 61.43 | 78.75 |
注:*表示与对照组比较,P<0.05。
Claims (7)
1.一种平肝胶囊,由如下重量份配比的原料药制成:
茵陈10-20份、龙胆草10-20份、黄芩10-20份、夏枯草10-20份、马鞭草10-20份、胆南星10-20份、绿豆10-20份、柴胡10-20份、紫草5-15份、郁金10-20份、虎杖10-20份、羚羊角5-15份、茯苓10-20份、枳壳15-25份、甘草5-15份、五味子10-20份、栀子10-20份、半枝莲10-20份、焦麦芽10-20份、焦山楂10-20份、焦神曲10-20份。
2.根据权利要求1所述的平肝胶囊,其特征在于,由如下重量份配比的原料药制成:
茵陈13-17份、龙胆草13-17份、黄芩13-17份、夏枯草13-17份、马鞭草13-17份、胆南星13-17份、绿豆13-17份、柴胡13-17份、紫草8-12份、郁金13-17份、虎杖13-17份、羚羊角8-12份、茯苓13-17份、枳壳18-22份、甘草8-12份、五味子13-17份、栀子13-17份、半枝莲13-17份、焦麦芽13-17份、焦山楂13-17份、焦神曲13-17份。
3.根据权利要求2所述的平肝胶囊,其特征在于,由如下重量份配比的原料药制成:
茵陈15份、龙胆草15份、黄芩15份、夏枯草15份、马鞭草15份、胆南星15份、绿豆15份、柴胡15份、紫草10份、郁金15份、虎杖15份、羚羊角10份、茯苓15份、枳壳20份、甘草10份、五味子15份、栀子15份、半枝莲15份、焦麦芽15份、焦山楂15份、焦神曲15份。
4.根据权利要求1或2或3所述的平肝胶囊,其特征在于,其剂型形式为口服制剂。
5.根据权利要求4所述的平肝胶囊,其特征在于,其剂型形式为胶囊剂。
6.权利要求1或2或3所述的平肝胶囊的制备方法,包含如下步骤:
(1)羚羊角研成细粉,过100目筛,备用;
(2)龙胆草、黄芩、胆南星、郁金、茯苓、五味子六味粉碎成细粉,得药粉A;
(3)其余茵陈等十四味药加水煎煮三次,第一次加药物重量8倍量水,第二、三次加药物重量6倍量水,每次煎煮2小时,过滤,合并煎液,浓缩至稠膏,干燥粉碎,得药粉B;
(4)将药粉A、药粉B与步骤(1)制得的羚羊角细粉混合使均匀,即得本发明平肝胶囊的活性物质;
(5)该活性物质单独或与药物可接受的辅料混合,按照制剂学常规方法制得。
7.权利要求1或2或3所述的平肝胶囊在制备治疗慢性乙型肝炎药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610795187.8A CN106215124A (zh) | 2016-08-31 | 2016-08-31 | 平肝胶囊及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610795187.8A CN106215124A (zh) | 2016-08-31 | 2016-08-31 | 平肝胶囊及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106215124A true CN106215124A (zh) | 2016-12-14 |
Family
ID=58073814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610795187.8A Pending CN106215124A (zh) | 2016-08-31 | 2016-08-31 | 平肝胶囊及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106215124A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107874092A (zh) * | 2017-11-25 | 2018-04-06 | 明光市绿园粮油贸易有限公司 | 一种治疗慢性肝炎的面粉及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103417684A (zh) * | 2013-08-13 | 2013-12-04 | 漳州片仔癀药业股份有限公司 | 一种茵胆平肝胶囊的制备方法 |
CN103720835A (zh) * | 2013-12-12 | 2014-04-16 | 济南新起点医药科技有限公司 | 一种复方三七平肝活血胶囊及其制备方法 |
CN104107342A (zh) * | 2014-07-24 | 2014-10-22 | 乔子恒 | 平肝降脂降血糖的药物 |
CN105327295A (zh) * | 2015-12-09 | 2016-02-17 | 赵爱良 | 一种治疗肝炎的胶囊及制备方法 |
-
2016
- 2016-08-31 CN CN201610795187.8A patent/CN106215124A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103417684A (zh) * | 2013-08-13 | 2013-12-04 | 漳州片仔癀药业股份有限公司 | 一种茵胆平肝胶囊的制备方法 |
CN103720835A (zh) * | 2013-12-12 | 2014-04-16 | 济南新起点医药科技有限公司 | 一种复方三七平肝活血胶囊及其制备方法 |
CN104107342A (zh) * | 2014-07-24 | 2014-10-22 | 乔子恒 | 平肝降脂降血糖的药物 |
CN105327295A (zh) * | 2015-12-09 | 2016-02-17 | 赵爱良 | 一种治疗肝炎的胶囊及制备方法 |
Non-Patent Citations (1)
Title |
---|
马蒲梅: "清肝健脾解郁汤治疗乙肝121例", 《光明中医》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107874092A (zh) * | 2017-11-25 | 2018-04-06 | 明光市绿园粮油贸易有限公司 | 一种治疗慢性肝炎的面粉及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102309716B (zh) | 一种治疗带下症的中药组合物及其制备方法 | |
CN111388582B (zh) | 一种用于新型冠状病毒肺炎的中药组合物及其制剂的应用 | |
CN100382815C (zh) | 一种治疗风湿痹痛的药物组合物及其制剂 | |
CN102210844B (zh) | 一种治疗慢性肝炎的中药组合物及其制备方法 | |
CN101683420B (zh) | 一种中药组合物在制备治疗急性咽炎药物中的应用 | |
CN106215124A (zh) | 平肝胶囊及其制备方法和应用 | |
CN101683423B (zh) | 一种中药组合物在制备治疗水痘药物中的应用 | |
CN100560089C (zh) | 用于治疗骨质疏松的中药制剂 | |
CN1634548A (zh) | 治疗病毒性肝炎的药物组合物及其制备方法 | |
CN104491459A (zh) | 一种治疗肿瘤的中药组合物 | |
CN103893634B (zh) | 一种治疗婴儿胆汁淤积的中药 | |
CN105616581A (zh) | 一种含有格列吡嗪的治疗糖尿病的药物组合物及其制备方法 | |
CN106266967A (zh) | 丹七软肝胶囊及其制备方法和应用 | |
CN1593493A (zh) | 辅康艾制剂及其制备方法 | |
CN104491567A (zh) | 一种治疗不安腿综合征的中药及其制备方法 | |
CN106362087A (zh) | 金羚胶囊及其制备方法和应用 | |
CN109663012A (zh) | 疏风清热,解毒利咽中药组合物及其制备方法与应用 | |
CN106266968A (zh) | 茵陈清肝利胆颗粒及其制备方法和应用 | |
CN106267082A (zh) | 养肝止痛胶囊及其制备方法和应用 | |
CN101554461B (zh) | 一种治疗银屑病的药物及其胶囊的制备方法 | |
CN101637533B (zh) | 一种中药组合物在制备治疗病毒性心肌炎药物中的应用 | |
CN1709448A (zh) | 一种治疗妇女疾病的藏药药物及其制备方法 | |
CN106361889B (zh) | 养心调肾颗粒及其制备方法和应用 | |
CN106361984A (zh) | 九味止血散及其制备方法和应用 | |
CN106389783A (zh) | 蚁丹羚胶囊及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Tang Jie Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |
|
RJ01 | Rejection of invention patent application after publication |